Brain Metastases Clinical Trials

41 studies are recruiting for brain metastases in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. A Phase II Study of Nivolumab With Ipilimumab and Cabozantinib in Patients With Untreated Renal Cell Carcinoma Brain Metastases

   A Phase II Study of Nivolumab with Ipilimumab and Cabozantinib in Patients with Untreated Renal Cell Carcinoma Brain Metastases

   Stage

   Phase 2

   Ages

   18 and older

   Site

   M D Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT05048212 on ClinicalTrials.gov

2. Laser Interstitial Thermal Therapy (LITT) or Surgery and Adjuvant Reirradiation for Recurrent Brain Metastases (LaSAR BeaM)

   standard paradigm for management of patients who present with concern for recurrence of brain metastases following initial stereotactic radiosurgery (SRS).

   Stage

   Phase 2

   Ages

   18 and older

   Site

   The University of Texas M. D. Anderson Cancer Center, Houston, Texas

   Run by

   M.D. Anderson Cancer Center

   See if you can join NCT07053033 on ClinicalTrials.gov

3. Brain Metastases in Greater Size - Hypofractionated Options Trial (BIGSHOT)

   This is a randomized, phase II trial comparing staged stereotactic radiosurgery (SSRS) versus fractionated stereotactic radiotherapy (FSRT) in patients with large brain metastases (≥2 cm and ≤5 cm). The study aims to evaluate efficacy, safety, and tumor response between these two standard-of-care r…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Medical University of South Carolina Hollings Cancer Center, Charleston, South Carolina

   Run by

   Medical University of South Carolina

   See if you can join NCT07227610 on ClinicalTrials.gov

4. SRS & Abemaciclib w/wo Imlunestrant in the Management of HR+/HER2- Breast CA Brain Metastases

   This is a single arm study of abemaciclib and endocrine therapy with stereotactic radiosurgery (SRS) among patients with hormone receptor (HR)+/HER2- metastatic breast cancer brain metastases.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ohio State University Comprehensive Cancer Center, Columbus, Ohio

   Locations

   2 in total

   Run by

   H. Lee Moffitt Cancer Center and Research Institute

   See if you can join NCT04923542 on ClinicalTrials.gov

5. Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

   BDTX-4933-101 is a first-in-human, open-label, Phase 1/2 dose escalation, dose optimization and expansion study designed to evaluate the safety and tolerability of S241656 as monotherapy and in combination with other anti-cancer therapies in participants with selected advanced malignancies. The stu…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Banner Health- MD Anderson Cancer Center, Gilbert, Arizona

   Locations

   49 in total

   Run by

   Institut de Recherches Internationales Servier

   See if you can join NCT05786924 on ClinicalTrials.gov

6. Development of MRF for Characterization of Brain Tumors After Radiotherapy

   The purpose of this study is to discover the potential convenience and ease of using a Magnetic Resonance Imaging (MRI) technique, named Magnetic Resonance Fingerprinting (or MRF), to achieve high-quality images within a short scan time of 5 min for viewing the entire brain. This is an advanced qua…

   Stage

   Not phased

   Ages

   18 to 60

   Site

   University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center, Cleveland, Ohio

   Locations

   2 in total

   Run by

   Case Comprehensive Cancer Center

   See if you can join NCT06101069 on ClinicalTrials.gov

7. Frameless Stereotactic Radiosurgery for Intact Brain Metastases

   This is a randomized study to determine if not treating planning target volume (PTV) margins during radiation therapy worsens progression free survival rates in patients with brain metastases.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT02747303 on ClinicalTrials.gov

8. Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases

   The purpose of this study is to determine whether AGuIX (Activation and Guidance of Irradiation by X-ray) gadolinium-based nanoparticles make radiation work more effectively in the treatment of patients with brain metastases that are more difficult to control with stereotactic radiation alone.

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Brigham and Women's Hospital

   See if you can join NCT04899908 on ClinicalTrials.gov

9. Personalized Radiotherapy for Individualized Treatment Strategies and Monitoring (PRISM)

   To characterize feasibility, safety, and/or preliminary efficacy of personalized strategies to adapt standard radiotherapy treatments to individual patient responses.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Ut Southwestern Medical Center, Dallas, Texas

   Run by

   University of Texas Southwestern Medical Center

   See if you can join NCT07139990 on ClinicalTrials.gov

10. MRI Biomarkers for Radiation-Induced Neurocognitive Decline Following SRS of Newly Diagnosed Brain Mets

    Brain metastases are a source of much morbidity and mortality in adults with primary solid malignant tumors. With improvements in systemic therapy that prolong survival but have limited central nervous system penetration, patients with brain metastases are at increasing risk of developing and exper…

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of North Carolina at Chapel Hill, Department of Radiation Oncology, Chapel Hill, North Carolina

    Run by

    UNC Lineberger Comprehensive Cancer Center

    See if you can join NCT04073966 on ClinicalTrials.gov

11. Memory Avoidance Whole Brain Radiotherapy vs Hippocampal Avoidance Whole Brain Radiotherapy (Athena 2 Trial)

    Participants in this research study have cancer that has spread to their brain, called brain metastases. One treatment for this type of cancer is called whole brain radiotherapy that stays away from a specific neurocognitive substructure, called the hippocampus, combined with medication to preserve…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio

    Run by

    Case Comprehensive Cancer Center

    See if you can join NCT07248228 on ClinicalTrials.gov

12. Phase I Study of Fractionated Stereotactic Radiation Therapy

    There is a lack of prospective trial data and consensus guidelines describing the use of Fractionated Stereotactic Radiation Therapy (FSRT) in the treatment of brain metastases. There has been no prospective dose escalation study performed to date to determine the maximum tolerated dose (MTD) in pa…

    Stage

    Not phased

    Ages

    18 and older

    Site

    Montefiore Medical Center, The Bronx, New York

    Run by

    Albert Einstein College of Medicine

    See if you can join NCT03726359 on ClinicalTrials.gov

13. Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases

    Radiosurgery is the use of a focal high dose of radiation therapy to ablate or kill a tumor. This trial will enroll patients with brain metastases 4 cm or less in greatest diameter and will compare 0mm margin to a 2mm margin for treatment.

    Stage

    Not phased

    Ages

    19 and older

    Site

    University of Alabama at Birmingham (UAB) Hazelrig-Salter Radiation Oncology Center, Birmingham, Alabama

    Run by

    University of Alabama at Birmingham

    See if you can join NCT06857006 on ClinicalTrials.gov

14. Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique

    Study patients will receive Whole-brain radiation therapy (WBRT) - pulsed reduced dose rate (PRDR) within 14 days of registration. All patients will receive single daily fractions using 3D conformal radiotherapy. A dose of 30 Gy in 10 fractions will be delivered using the PRDR technique.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Froedtert Hospital & the Medical College of Wisconsin, Milwaukee, Wisconsin

    Locations

    2 in total

    Run by

    Medical College of Wisconsin

    See if you can join NCT05045950 on ClinicalTrials.gov

15. Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

    The purpose of this research is to see if monitoring the brain using magnetic resonance imaging (MRI) after radiation therapy will allow investigators to find cancer that has spread to the brain (brain metastases) before it causes symptoms.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Wake Forest Baptist Comprehensive Cancer Center, Winston-Salem, North Carolina

    Run by

    Wake Forest University Health Sciences

    See if you can join NCT05692635 on ClinicalTrials.gov

16. A Phase II Study of Tucatinib and Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Metastatic Solid Tumors and Metastases to Brain (TUCATEMEB)

    To learn if the study drugs, tucatinib and adotrastuzumab emtansine (T-DM1), can help to control solid tumors that have spread to the brain.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    M D Anderson Cancer Center, Houston, Texas

    Run by

    M.D. Anderson Cancer Center

    See if you can join NCT05673928 on ClinicalTrials.gov

17. Stereotactic Radiosurgery Dose Escalation for Brain Metastases

    This is a Phase I dose escalation and expansion trial. The purpose of this study is to determine the maximum tolerated dose of radiation received during stereotactic radiosurgery in patients with brain metastases who have never received radiation to the brain before.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Huntsman Cancer Institute, Salt Lake City, Utah

    Run by

    University of Utah

    See if you can join NCT02390518 on ClinicalTrials.gov

18. REMASTer: REcurrent Brain Metastases After SRS Trial

    Randomized, post-market multi-center study investigating the efficacy of two sets of treatment algorithms in brain metastases (BM) patients at the time of first intervention for radiographic progression after stereotactic radiosurgery (SRS), with or without surgery.

    Stage

    Not phased

    Ages

    18 and older

    Site

    UCLA, Los Angeles, California

    Locations

    9 in total

    Run by

    Monteris Medical

    See if you can join NCT05124912 on ClinicalTrials.gov

19. A Study of Stereotactic Radiosurgery (SRS) for People With Lung Cancer That Has Spread to the Brain

    The purpose of the study is to see if stereotactic radiosurgery/SRS is an effective treatment for people with a new diagnosis of brain metastases from small cell lung cancer/SCLC.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Memorial Sloan Kettering at Basking Ridge, Basking Ridge, New Jersey

    Locations

    7 in total

    Run by

    Memorial Sloan Kettering Cancer Center

    See if you can join NCT05419076 on ClinicalTrials.gov

20. Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

    Stereotactic radiosurgery (SRS) is a commonly used treatment for brain tumors. It is a one-day (or in some cases two day), out-patient procedure during which a high dose of radiation is delivered to small spots in the brain while excluding the surrounding normal brain. Whole brain radiation therapy…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    University of Arizona Cancer Center-Orange Grove Campus, Tucson, Arizona

    Locations

    86 in total

    Run by

    Canadian Cancer Trials Group

    See if you can join NCT03550391 on ClinicalTrials.gov

21. MeDex: No Perioperative Dexamethasone in Brain Metastases

    Perioperative treatment of newly diagnosed cancer patients with brain metastasis without dexamethasone (Dex).

    Stage

    Not phased

    Ages

    18 and older

    Site

    University of Louisville Hospital, Louisville, Kentucky

    Run by

    University of Louisville

    See if you can join NCT07044557 on ClinicalTrials.gov

22. 18F-Fluciclovine PET Amino Acid Evaluation of Brain Metastasis Treated With Stereotactic Radiosurgery

    This is a pilot imaging study in participants treated with stereotactic radiosurgery (SRS) to treat brain metastasis. The purpose of this study is to see whether 18F-Fluciclovine positron emission tomography (PET) can be used as a biomarker to measure response or progression of brain metastasis aft…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Miami Cancer Institute, Miami, Florida

    Run by

    Baptist Health South Florida

    See if you can join NCT06048094 on ClinicalTrials.gov

23. Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain Metastases

    This is a multicenter, phase II trial of relatlimab (rela), nivolumab (nivo), and ipilimumab (ipi) in patients with asymptomatic and symptomatic melanoma brain metastases.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Stanford University, Palo Alto, California

    Run by

    Stanford University

    See if you can join NCT06712927 on ClinicalTrials.gov

24. Assess Use of 18F-Fluciclovine for Patients With Large Brain Metastases Treated With Staged Stereotactic Radiosurgery

    The spread of cancer to the brain is referred to as brain metastases. Brain metastases are a common complication of cancer. This study is being done to determine whether the use of a new imaging agent, 18F-fluciclovine, is able to detect which patients are responding to radiation therapy. In additi…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Miami Cancer Institute, Miami, Florida

    Run by

    Baptist Health South Florida

    See if you can join NCT04689048 on ClinicalTrials.gov

25. Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1

    Adult patients with primary or secondary central nervous system malignancies will be invited to undergo a baseline [C-11]-CS1P1 PET scan and a follow-up scan within 24 months of the baseline scan (preferably within 6-months post-treatment).The study will describe patterns of tracer uptake in tumors…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Washington University School of Medicine, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT07462507 on ClinicalTrials.gov